Inhaled bronchodilators for cystic fibrosis
Información
- DOI:
- https://doi.org/10.1002/14651858.CD003428.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 19 octubre 2005see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Fibrosis quística y enfermedades genéticas
- Copyright:
-
- Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Dr Halfhide co‐ordinated the changing of the protocol into a full review. This included undertaking searches, appraising quality of papers, data extraction, entering data into RevMan, analysis, interpretation of data and writing the review. Dr Halfhide acts as guarantor of the review.
Dr Couriel originally conceived the idea for the protocol and review. He was the lead author of the protocol. He provided advice throughout the selection of the eligible studies, data interpretation and the writing of the review.
Dr Evans provided useful comments and ideas throughout conception of the protocol. During the review she provided help with appraising the quality of the studies, data extraction and interpretation of results.
Declarations of interest
None known.
Acknowledgements
Cochrane Cystic Fibrosis & Genetic Disorders Review Group at the Royal Liverpool Children's Hospital.
Version history
| Published | Title | Stage | Authors | Version |
| 2016 Feb 11 | Inhaled bronchodilators for cystic fibrosis | Review | Clare Halfhide, Hazel J Evans, Jon Couriel | |
| 2005 Oct 19 | Inhaled bronchodilators for cystic fibrosis | Review | Clare Halfhide, Hazel J Evans, Jon Couriel | |
| 2002 Jan 21 | Inhaled bronchodilators for cystic fibrosis | Protocol | Jon Couriel, H Bunn, Hazel J Evans | |
Differences between protocol and review
There was a post hoc change to the types of bronchodilators to be included in the review. There is now a fourth category 'long‐acting anticholinergics agents (tiotropium)' due to the fact that these preparations are now commercially available.
